Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorNorthwell Health
About this trial
This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms:
Arm 1: Standard of Care (SOC) and active rTMS Arm 2: Standard of Care (SOC) and sham rTMS
Each participant will receive rTMS five days per week, for four consecutive weeks. Functional magnetic resonance imaging (fMRI) scans, clinical assessments, and cognitive tests will be performed at baseline, end of the 2nd week, and end of the 4th week.
Eligibility criteria
Qualifiers
Male or female subjects 18 to 60 years of age
DSM-V diagnosis of schizophrenia spectrum disorders
Competent to provide informed consent
Disqualifiers
Lifetime DSM-V diagnosis of an Axis-I disorder other than schizophrenia spectrum disorders
Lifetime diagnosis of ataxia or other cerebellar disorders
Lifetime diagnosis of mental retardation, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, or other neurodegenerative disorders
Any active general medical condition or CNS disease which can affect cognition or response to treatment
Trial design
Treatments tested in this trial
- Transcranial Magnetic Stimulation
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov